The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
From targeted metagenomics on almost 300 soil samples, researchers saw evidence for microbiome gene clusters associated with natural product biosynthesis in NYC parks.
The partners will combine genome editing approaches with Watson's computational and machine learning methods to study drug-resistance in tumors.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
The researchers identified 122 potential immune response drivers that could serve as targets for drug research efforts.
The researchers identified new combinations of mutated genes and drugs that could provide the platform for future cancer therapies.
Backed by $12 million from a recent Series A financing and a strategic partnership with Thermo Fisher Scientific, the Ann Arbor, Michigan-based firm plans to sequence the tumors of 100,000 advanced cancer patients over three years.
Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
Elaine Mardis of Washington University in St. Louis described genome-guided efforts to identify neoantigen targets for cancer vaccines in melanoma and other cancer types.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.